Cargando…

Correction: Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055765/ http://dx.doi.org/10.1371/journal.pone.0100604

Ejemplares similares

Correction: Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II
por: Dituri, Francesco, et al.
Publicado: (2013)

Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II
por: Dituri, Francesco, et al.
Publicado: (2013)

Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts
por: Maier, Armin, et al.
Publicado: (2015)

LY2157299 Monohydrate, a TGF-βR1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer
por: Zhang, Qing, et al.
Publicado: (2018)

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study
por: Kovacs, Richard J., et al.
Publicado: (2014)

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
por: Herbertz, Stephan, et al.
Publicado: (2015)

Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats
por: Liu, X., et al.
Publicado: (2016)

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor
por: Yingling, Jonathan M., et al.
Publicado: (2017)

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients
por: Serova, Maria, et al.
Publicado: (2015)

TGF-β receptor inhibitor LY2109761 enhances the radiosensitivity of gastric cancer by inactivating the TGF-β/SMAD4 signaling pathway
por: Yang, Tian, et al.
Publicado: (2019)

LY6K depletion modulates TGF‐β and EGF signaling
por: Park, Sujeong, et al.
Publicado: (2023)

Reversal of β cell de-differentiation by a small molecule inhibitor of the TGFβ pathway
por: Blum, Barak, et al.
Publicado: (2014)

Polymeric Nano-Micelles as Novel Cargo-Carriers for LY2157299 Liver Cancer Cells Delivery
por: Hanafy, Nemany Abdelhamid Nemany, et al.
Publicado: (2018)

Correction to: Monoclonal Antibody to Marinobufagenin Downregulates TGFβ Profibrotic Signaling in Left Ventricle and Kidney and Reduces Tissue Remodeling in Salt‐Sensitive Hypertension
Publicado: (2022)

Development and characterization of human monoclonal antibodies that neutralize multiple TGFβ isoforms
por: Bedinger, Daniel, et al.
Publicado: (2015)

Role of TGF-β 1 and TGF-β Type II Receptor in Gastric Cancer
por: Park, Dong Il, et al.
Publicado: (2002)

TGF-β sensitivity is determined by N-linked glycosylation of the type II TGF-β receptor
por: Kim, Young-Woong, et al.
Publicado: (2012)

Therapeutic Effect of Polymeric Nanomicelles Formulation of LY2157299-Galunisertib on CCl(4)-Induced Liver Fibrosis in Rats
por: Panzarini, Elisa, et al.
Publicado: (2022)

Correction to: microRNA-193a stimulates pancreatic cancer cell repopulation and metastasis through modulating TGF-β2/TGF-βRIII signalings
por: Fang, Chi, et al.
Publicado: (2021)

Pentabromopseudilin: a myosin V inhibitor suppresses TGF-β activity by recruiting the type II TGF-β receptor to lysosomal degradation
por: Shih-Wei, Wang, et al.
Publicado: (2018)

TβRIII independently binds type I and type II TGF-β receptors to inhibit TGF-β signaling
por: Tazat, Keren, et al.
Publicado: (2015)

Direct and Indirect Effect of TGFβ on Treg Transendothelial Recruitment in HCC Tissue Microenvironment
por: Dituri, Francesco, et al.
Publicado: (2021)

The TGFβ type I receptor TGFβRI functions as an inhibitor of BMP signaling in cartilage
por: Wang, Weiguang, et al.
Publicado: (2019)

TGFβ-mediated expression of TGFβ-activating integrins in SSc monocytes: disturbed activation of latent TGFβ?
por: van Caam, A., et al.
Publicado: (2020)

Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Publicado: (2020)

Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
por: Giannelli, Gianluigi, et al.
Publicado: (2021)

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
por: Holmgaard, Rikke B., et al.
Publicado: (2018)

Mechanism of action and efficacy of LY2109761, a TGF-β receptor inhibitor, targeting tumor microenvironment in liver cancer after TACE
por: He, Xiaojun, et al.
Publicado: (2017)

Correction: Characterization of Negative Feedback Network Motifs in the TGF-β Signaling Pathway
por: Nicklas, Daniel, et al.
Publicado: (2014)

Correction to: ALG3 contributes to stemness and radioresistance through regulating glycosylation of TGF-β receptor II in breast cancer
por: Sun, Xiaoqing, et al.
Publicado: (2022)

Correction: TGF-β Prevents Phosphate-Induced Osteogenesis through Inhibition of BMP and Wnt/β-Catenin Pathways
Publicado: (2014)

Liberating TGFβ
por: Leslie, Mitch
Publicado: (2007)

TGF-β Signaling
por: Tzavlaki, Kalliopi, et al.
Publicado: (2020)

Fortilin interacts with TGF-β1 and prevents TGF-β receptor activation
por: Pinkaew, Decha, et al.
Publicado: (2022)

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
por: Li, Yiwen, et al.
Publicado: (2018)

Correction for Targeted inactivation of β1 integrin induces β3 integrin switching, which drives breast cancer metastasis by TGF-β
Publicado: (2014)

RepSox, a small molecule inhibitor of the TGFβ receptor, induces brown adipogenesis and browning of white adipocytes
por: Tu, Wan-zhi, et al.
Publicado: (2019)

Pentabromophenol suppresses TGF-β signaling by accelerating degradation of type II TGF-β receptors via caveolae-mediated endocytosis
por: Chen, Chun-Lin, et al.
Publicado: (2017)

A novel GPI-anchored dominant-negative TGF-β receptor II renders T cells unresponsive to TGF-β signaling
por: Petersen, Sven H., et al.
Publicado: (2023)

TGF-β Inhibitors for Therapeutic Management of Kidney Fibrosis
por: Park, Cheol Ho, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f5n1rb4dl6sfrbqp43htqccjb1